We are live on
!
Find out more
DCM
Defilade Capital Management Portfolio holdings
AUM
$747M
This Fund
S&P 500
This Quarter
Est. Return
+36.31%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$738M
AUM Growth
–
Cap. Flow
+$677M
Cap. Flow
% of AUM
91.82%
Top 10 Holdings %
Top 10 Hldgs %
55.1%
Holding
33
New
33
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
quarters
Top 10 Avg Time Held
0
quarters
Top 20 Avg Time Held
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$55.6M |
| 2 |
AbbVie
ABBV
|
+$51.9M |
| 3 |
Novartis
NVS
|
+$47.5M |
| 4 |
ICU Medical
ICUI
|
+$45.6M |
| 5 |
Steris
STE
|
+$34M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$161B
| $54.9M | 7.44% |
+2,203,504
| New | +$55.6M |
2025 Q4
0 quarters
|
|
|
2
AbbVie
ABBV
$489B
| $52M | 7.05% |
+227,669
| New | +$51.9M |
2025 Q4
0 quarters
|
|
|
3
Novartis
NVS
$273B
| $50M | 6.78% |
+362,816
| New | +$47.5M |
2025 Q4
0 quarters
|
|
|
4
ICU Medical
ICUI
$4.01B
| $48.6M | 6.59% |
+340,745
| New | +$45.6M |
2025 Q4
0 quarters
|
|
5
PACS Group
PACS
$6.86B
| $44M | 5.96% |
+1,145,485
| New | +$25.1M |
2025 Q4
0 quarters
|
|
6
Eli Lilly
LLY
$1.05T
| $34.3M | 4.65% |
+31,950
| New | +$30.5M |
2025 Q4
0 quarters
|
|
|
7
Steris
STE
$20.9B
| $34.3M | 4.65% |
+135,307
| New | +$34M |
2025 Q4
0 quarters
|
|
8
Olema Pharmaceuticals
OLMA
$684M
| $30.9M | 4.18% |
+1,234,634
| New | +$22M |
2025 Q4
0 quarters
|
|
9
Revolution Medicines
RVMD
$40.7B
| $28.9M | 3.92% |
+363,454
| New | +$23.8M |
2025 Q4
0 quarters
|
|
10
Biogen
BIIB
$33.3B
| $28.5M | 3.86% |
+161,992
| New | +$26.5M |
2025 Q4
0 quarters
|
|
|
NUVL
11
DELISTED
Nuvalent
NUVL
| $27.1M | 3.67% |
+269,043
| New | +$26.5M |
2025 Q4
0 quarters
|
|
12
Intuitive Surgical
ISRG
$150B
| $25.9M | 3.51% |
+45,662
| New | +$24.3M |
2025 Q4
0 quarters
|
|
13
Henry Schein
HSIC
$9.36B
| $24.2M | 3.28% |
+320,422
| New | +$22.5M |
2025 Q4
0 quarters
|
|
14
Globus Medical
GMED
$10B
| $23.3M | 3.16% |
+267,212
| New | +$20.3M |
2025 Q4
0 quarters
|
|
15
Xencor
XNCR
$1.83B
| $21.7M | 2.94% |
+1,414,755
| New | +$21.1M |
2025 Q4
0 quarters
|
|
16
Cogent Biosciences
COGT
$5.38B
| $20.2M | 2.74% |
+568,619
| New | +$16M |
2025 Q4
0 quarters
|
|
17
Align Technology
ALGN
$10.1B
| $20M | 2.71% |
+128,060
| New | +$18.4M |
2025 Q4
0 quarters
|
|
18
Ascendis Pharma A/S
ASND
$15.1B
| $18.3M | 2.48% |
+85,694
| New | +$17.7M |
2025 Q4
0 quarters
|
|
19
DexCom
DXCM
$31.7B
| $16.3M | 2.2% |
+244,881
| New | +$15.8M |
2025 Q4
0 quarters
|
|
20
Becton Dickinson
BDX
$50.1B
| $15.8M | 2.14% |
+81,207
| New | +$15.5M |
2025 Q4
0 quarters
|
|
21
AtriCure
ATRC
$2.84B
| $15.7M | 2.13% |
+397,636
| New | +$14.6M |
2025 Q4
0 quarters
|
|
22
LivaNova
LIVN
$4.21B
| $14.9M | 2.01% |
+241,413
| New | +$13.8M |
2025 Q4
0 quarters
|
|
23
Alphatec Holdings
ATEC
$1.65B
| $13.2M | 1.79% |
+626,754
| New | +$11.6M |
2025 Q4
0 quarters
|
|
24
Denali Therapeutics
DNLI
$3.11B
| $10.8M | 1.47% |
+656,713
| New | +$11.1M |
2025 Q4
0 quarters
|
|
25
Glaukos
GKOS
$9.77B
| $10.4M | 1.4% |
+91,703
| New | +$8.76M |
2025 Q4
0 quarters
|
|
Similar funds
BG
PCM
JA
ECM
AAM
VCM
IWP
CCME
Defilade Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Defilade Capital Management, which disclosed 33 positions worth $738M. Its ten largest holdings account for 55% of the portfolio.
Its largest position is Pfizer: 2,203,504 shares worth $54.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Defilade Capital Management's largest Q4 2025 buy was Pfizer: 2,203,504 shares worth $54.9M.
- Defilade Capital Management's ten largest holdings make up 55% of its $738M portfolio in Q4 2025.
- Defilade Capital Management disclosed 33 positions in Q4 2025, its first 13F filing on record.
Based on Defilade Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.